



6-8
OCTOBER
2023

INTERCONTINENTAL,
FESTIVAL CITY, DUBAI,
UNITED ARAB EMIRATES

BREAST CANCER SESSION



07 OCTOBER 2023
(SATURDAY)



08:00 - 16:30 HRS
UAE TIME



IN-PERSON



AL RAS 2

Congress Secretariat



In collaboration with



Supported By



In conjunction with



cancercongress.ae

BREAST CANCER SESSION



07 OCTOBER 2023
 (SATURDAY)



08:00 - 16:30 HRS
 UAE TIME



IN-PERSON



AL RAS 2

SESSION 1

Chairperson:	Sudeep Gupta, India Archana Shetty, UAE Khalid Balaraj, UAE
08:00	Opening Remarks Shaheenah Dawood, UAE
08:00 - 08:15	How the Introduction of the Oral SERDs will affect the current treatment landscape, Guidelines updates - Supported by Menarini Giuseppe Curigliano, Italy
08:15 - 08:30	Important Data in 2022/2023: What Worked and What Didn't Stephen Johnston, UK
08:30 - 08:45	Evolving paradigm in management of metastatic HER2+ Breast Cancer - Supported by MSD Emad Anwar Dawoud, UAE
08:45 - 09:00	Where we are headed in Breast Cancer Management: A Look into the Future Javier Cortes, Spain
09:00 - 09:15	The Rise of CDK4/6 Inhibitors in HR+/HER2- Early Breast Cancer: Impact For Patients - Supported by Novartis Moderator: Aydah Al Awadhi, UAE Speaker: Michael Gnant, Austria
09:15 - 09:30	Role of PARPi in the management of eBC patients harbouring gBRCA - Supported by AstraZeneca Fathi Azribi, UAE
09:30 - 09:45	Node Positive, HR+, HER2- Early Breast Cancer, which patients in your practice need more? - Supported By Lilly Moderator: Aydah Al Awadhi, UAE Speaker: Giuseppe Curigliano, Italy
09:45 - 10:05	Young Women with Breast Cancer: Challenging questions in Breast Cancer Management Moderator: Nitesh Rohatgi, India Panel: Tanya Rohatgi, India Stephen Johnston, UK, Sudeep Gupta, India Giuseppe Curigliano, Italy Aydah Al Awadhi, UAE Dalia El Shorbagy, UAE Nihal Yildirim, UAE Michael Gnant, Austria Aref Chehal, UAE Nouri Bennini, UAE
10:05 - 10:25	Coffee Break



07 OCTOBER 2023
 (SATURDAY)



08:00 - 16:30 HRS
 UAE TIME



IN-PERSON



AL RAS 2

SESSION 2 Expanding the Realm of HER2

Chairperson:	Nitesh Rohatgi, India Archana Shetty, UAE Patrizia Porcu, UAE
10:25 - 10:40	Highlights from the EMERALD on the ESR1m patients - <i>Supported by</i> Menarini Javier Cortes, Spain
10:40 - 10:55	HER2 low breast cancer: What challenges are we going to face? Giuseppe Curigliano, Italy
10:55 - 11:10	Improving outcomes in HER2+ early Breast Cancer - <i>Supported by</i> Pierre Fabre Shaheenah Dawood, UAE
11:10 - 11:30	Tumor board: HER2 low breast cancer Moderator: Hamdy Abdul Azim, Egypt Panel: Aladdin Maaraoui, UAE Aydah Al Awadhi, UAE Diaeddine Trad, UAE Ramanujam Singarachari, UAE Basel Altrabulsi, UAE Mohanad Diab, UAE
11:30 - 11:45	Optimal Sequencing in HER2 positive MBC: Are we there yet? Javier Cortes, Spain
11:45 - 12:00	TAILOR and RESPOND: A Focus On OncotypeDX in Early Breast Cancer - <i>Supported by</i> New Bridge Fathi Azribi, UAE
12:00 - 12:20	Tumor board: Challenging Cases in HER2 Positive Breast Cancer Moderator: Mohsen Mokhtar, Egypt Panel: Nita Nair, India Sonia Otsmane, UAE Rham Zaki Ahmed, UAE Hamdy Abdul Azim, Egypt Nadia Abdelwahed, UAE Chandragouda Dodagoudar, India
12:20 - 12:35	Risk of recurrence in eBC HR+ HER2-: Do we need more? - <i>Supported by</i> Novartis Moderator: Aydah Al Awadhi, UAE Speaker: Michael Gnant, Austria
12:35 - 12:50	Reimagine HER2+ Breast Cancer Care with Phesgo - <i>Supported by</i> Roche Maroun El Khoury, UAE
12:50 - 13:50	Lunch Break



07 OCTOBER 2023
 (SATURDAY)



08:00 - 16:30 HRS
 UAE TIME



IN-PERSON



AL RAS 2

SESSION 3

Integrating Novel Therapies in HR Positive Breast Cancer

Chairperson:	Nihal Yildirim, UAE Milicent Bello, UAE Mohanad Diab, UAE
13:50 - 14:05	Role of GnRHa in management of patients with BC - <i>Supported by</i> IPSEN Maroun El Khoury, UAE
14:05 - 14:20	Role of Trop-2 ADCs in mTNBC Management - <i>Supported by</i> GILEAD Aydah Al Awadhi, UAE
14:20 - 14:35	Tailored Strategies in HR+ HER2- Metastatic Breast Cancer - <i>Supported by</i> Lilly Moderator: Aydah Al Awadhi, UAE Speaker: Emad Anwar Dawoud, UAE
14:35 - 14:50	Rapid Fire Round: Challenging Questions in Testing and Treating Patients with ESR1 Mutation - <i>Supported by</i> Menarini Moderator: Shaheenah Dawood, UAE Panelist: Javier Cortes, Spain Giuseppe Curigliano, Italy
14:50 - 15:05	Neulastim® Onpro® On Body Injector Kit: Efficacy, Safety & Convenience Data - <i>Supported by</i> Kyowa Kirin Shaheenah Dawood, UAE
15:05 - 15:20	Novel Endocrine Therapeutic Agents in the MBC Stephen Johnston, UK
15:20 - 15:40	Tumor Board: Optimally Integrating Adjuvant Endocrine Therapy Moderator: Sudeep Gupta, India Panelists: Nitesh Rohatgi, India Mohsen Mokhtar, Egypt OmalKhair Abulkhair, KSA Emad Anwar Dawood, UAE Basel Altrabulsi, UAE Millicent Bello, UAE
15:40 - 16:00	Rapid Fire Round: Endocrine Therapy in HR +ve /HER2 -ve MBC - <i>Supported by</i> Novartis Moderator: Shaheenah Dawood, UAE Panelists: Dalia El Shorbagy, UAE Emad Anwar Dawoud, UAE Fathi Azribi, UAE
16:00 - 16:20	Tumor Board: Integrating ADCs in the Management of HR+ve Breast Cancer Moderator: Hassan Shahryar Sheikh, UAE Panelists: Diaeddine Trad, UAE Nouri Bennini, UAE Basel Altrabulsi, UAE Fadi El Karak, Lebanon Abhinav Ahluwalia, UAE Mohanad Diab, UAE

16:20 - 16:30 Q&A and Closing Remarks